{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:14:52Z","timestamp":1788052492978,"version":"build-2784847793"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["252102311176"],"award-info":[{"award-number":["252102311176"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["262102311200"],"award-info":[{"award-number":["262102311200"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304286"],"award-info":[{"award-number":["82304286"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M773579"],"award-info":[{"award-number":["2025M773579"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119185","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T15:45:52Z","timestamp":1785858352000},"page":"119185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A comprehensive review of the mechanism and application prospect of PARP dual-target inhibitors in tumor treatment"],"prefix":"10.1016","volume":"318","author":[{"given":"Yi-Ru","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Ru","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Jie","family":"Seng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6771-9421","authenticated-orcid":false,"given":"Hong-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119185_bib1","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/s41388-022-02290-1","article-title":"Malignant peripheral nerve sheath tumor: models, biology, and translation","volume":"41","author":"Somatilaka","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.119185_bib2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119185_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100677","article-title":"Emerging trends in clinical allogeneic CAR cell therapy","volume":"6","author":"Li","year":"2025","journal-title":"Med"},{"key":"10.1016\/j.ejmech.2026.119185_bib4","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/s41392-021-00728-8","article-title":"Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy","volume":"6","author":"Kang","year":"2021","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119185_bib5","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41573-023-00713-6","article-title":"Small-molecule discovery through DNA-encoded libraries","volume":"22","author":"Peterson","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119185_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70314","article-title":"PARP (poly ADP-ribose polymerase) family in health and disease","volume":"6","author":"Lei","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.ejmech.2026.119185_bib7","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1038\/s41467-022-33028-y","article-title":"Lagging strand gap suppression connects BRCA-mediated fork protection to nucleosome assembly through PCNA-dependent CAF-1 recycling","volume":"13","author":"Thakar","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119185_bib8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","article-title":"PARP inhibitor resistance: the underlying mechanisms and clinical implications","volume":"19","author":"Li","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119185_bib9","first-page":"222","article-title":"Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer","author":"Roskoski","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.119185_bib10","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12943-025-02355-1","article-title":"Clinical approaches to overcome PARP inhibitor resistance","volume":"24","author":"Zou","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119185_bib11","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.tcb.2019.07.008","article-title":"PARP inhibitor resistance: a tug-of-war in BRCA-mutated cells","volume":"29","author":"Noordermeer","year":"2019","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119185_bib12","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41467-023-35880-y","article-title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","volume":"14","author":"Tsujino","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119185_bib13","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ijrobp.2020.01.030","article-title":"Combination therapy with radiation and PARP inhibition enhances responsiveness to Anti-PD-1 therapy in colorectal tumor models","volume":"108","author":"Seyedin","year":"2020","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ejmech.2026.119185_bib14","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.ccell.2024.10.015","article-title":"Elucidating acquired PARP inhibitor resistance in advanced prostate cancer","volume":"42","author":"Seed","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.119185_bib15","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1158\/0008-5472.CAN-24-0293","article-title":"The USP1 inhibitor KSQ-4279 overcomes PARP inhibitor resistance in homologous recombination-deficient tumors","volume":"84","author":"Cadzow","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119185_bib16","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.ccell.2021.06.018","article-title":"PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity","volume":"39","author":"Gozgit","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.119185_bib17","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1158\/2159-8290.CD-23-1220","article-title":"BRCA1-Mediated dual regulation of ferroptosis exposes a vulnerability to GPX4 and PARP Co-Inhibition in BRCA1-Deficient cancers","volume":"14","author":"Lei","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.119185_bib18","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119185_bib19","article-title":"Targeting HDAC and PARP enhances STING-dependent antitumor immunity in STING-deficient tumor","volume":"12","author":"Mao","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.ejmech.2026.119185_bib20","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.1007\/s11030-025-11456-4","article-title":"Structure-guided design and DFT-based optimization of natural product-derived dual inhibitors targeting CDK-1 and PARP-1","volume":"30","author":"Bhambri","year":"2026","journal-title":"Mol. Divers."},{"key":"10.1016\/j.ejmech.2026.119185_bib21","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/s41416-021-01664-8","article-title":"Combined PARP and HSP90 inhibition: preclinical and Phase 1 evaluation in patients with advanced solid tumours","volume":"126","author":"Konstantinopoulos","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119185_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103607","article-title":"Dual-target inhibitors of PARP1 in cancer therapy: a drug discovery perspective","volume":"28","author":"Zhang","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119185_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.114094","article-title":"Dual-target inhibitors of poly (ADP-ribose) polymerase-1 for cancer therapy: advances, challenges, and opportunities","volume":"230","author":"Hu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106529","article-title":"Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy","volume":"186","author":"Peng","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.119185_bib25","article-title":"Antitumor activity and structure\u2013activity relationship of poly (ADP-ribose) polymerase (PARP)-based dual inhibitors","volume":"41","author":"Yang","year":"2025","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib26","doi-asserted-by":"crossref","first-page":"16099","DOI":"10.1021\/acs.jmedchem.2c01352","article-title":"Multi-therapies based on PARP inhibition: potential therapeutic approaches for cancer treatment","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib27","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13046-025-03441-4","article-title":"PARP-1 as a novel target in endocrine-resistant breast cancer","volume":"44","author":"Zicarelli","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119185_bib28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40265-022-01703-5","article-title":"PARP inhibition, a new therapeutic avenue in patients with prostate cancer","volume":"82","author":"Flippot","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2026.119185_bib29","doi-asserted-by":"crossref","first-page":"16464","DOI":"10.1021\/acs.jmedchem.3c00865","article-title":"Advances in development of selective Antitumor inhibitors that target PARP-1","volume":"66","author":"Liu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib30","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.tibs.2021.01.014","article-title":"Rapid detection and signaling of DNA damage by PARP-1","volume":"46","author":"Pandey","year":"2021","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ejmech.2026.119185_bib31","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119185_bib32","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s10020-025-01278-3","article-title":"PARP3 promotes macrophage inflammation via mono ADP ribosylation of Ppia Glu140","volume":"31","author":"Fan","year":"2025","journal-title":"Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119185_bib33","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13073-024-01328-1","article-title":"PARP4 interacts with hnRNPM to regulate splicing during lung cancer progression","volume":"16","author":"Lee","year":"2024","journal-title":"Genome Med."},{"key":"10.1016\/j.ejmech.2026.119185_bib34","doi-asserted-by":"crossref","first-page":"8754","DOI":"10.1038\/s41467-024-53068-w","article-title":"Tankyrase inhibition promotes endocrine commitment of hPSC-derived pancreatic progenitors","volume":"15","author":"Poon","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119185_bib35","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2309047120","article-title":"PARP7-mediated ADP-ribosylation of FRA1 promotes cancer cell growth by repressing IRF1- and IRF3-dependent apoptosis","volume":"120","author":"Manetsch","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2026.119185_bib36","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12974-025-03374-x","article-title":"PARP9 exacerbates apoptosis and neuroinflammation via the PI3K pathway in the thalamus and hippocampus and cognitive decline after cortical infarction","volume":"22","author":"Liao","year":"2025","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.ejmech.2026.119185_bib37","doi-asserted-by":"crossref","first-page":"6197","DOI":"10.1038\/s41467-024-50429-3","article-title":"PARP10 promotes the repair of nascent strand DNA gaps through RAD18 mediated translesion synthesis","volume":"15","author":"Khatib","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119185_bib38","article-title":"PARP11 inhibition inactivates tumor-infiltrating regulatory T cells and improves the efficacy of immunotherapies","volume":"5","author":"Basavaraja","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ejmech.2026.119185_bib39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41413-024-00363-3","article-title":"IRF1-mediated upregulation of PARP12 promotes cartilage degradation by inhibiting PINK1\/Parkin dependent mitophagy through ISG15 attenuating ubiquitylation and SUMOylation of MFN1\/2","volume":"12","author":"Deng","year":"2024","journal-title":"Bone Res."},{"key":"10.1016\/j.ejmech.2026.119185_bib40","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13046-025-03439-y","article-title":"PARP9-PARP13-PARP14 axis tunes colorectal cancer response to radiotherapy","volume":"44","author":"Prokarenkaite","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119185_bib41","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.1080\/15548627.2020.1847799","article-title":"PARP14 inhibits microglial activation via LPAR5 to promote post-stroke functional recovery","volume":"17","author":"Tang","year":"2021","journal-title":"Autophagy"},{"key":"10.1016\/j.ejmech.2026.119185_bib42","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/j.apsb.2020.12.010","article-title":"SMYD3\u2013PARP16 axis accelerates unfolded protein response and mediates neointima formation","volume":"11","author":"Long","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119185_bib43","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1093\/nar\/gkz120","article-title":"Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins","volume":"47","author":"Alemasova","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.119185_bib44","article-title":"Stanniocalcin-1 promotes PARP1-Dependent cell death via JNK activation in colitis","volume":"11","author":"Zhu","year":"2024","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.ejmech.2026.119185_bib45","volume":"120","author":"Lu","year":"2023"},{"key":"10.1016\/j.ejmech.2026.119185_bib46","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2026.2656053","article-title":"PARP7 inhibition and a STING agonist potentiate radiation-induced immunogenicity in glioblastoma","volume":"15","author":"Lippert","year":"2026","journal-title":"OncoImmunology"},{"key":"10.1016\/j.ejmech.2026.119185_bib47","doi-asserted-by":"crossref","first-page":"5983","DOI":"10.1038\/s41467-023-41737-1","article-title":"PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNgamma-driven acquired resistance in preclinical cancer models","volume":"14","author":"Wong","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119185_bib48","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","article-title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","volume":"18","author":"Chang","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119185_bib49","doi-asserted-by":"crossref","first-page":"12492","DOI":"10.1093\/nar\/gkad1064","article-title":"Structural and biochemical analysis of the PARP1-homology region of PARP4\/vault PARP","volume":"51","author":"Frigon","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2026.119185_bib50","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.119185_bib51","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2025.2542358","article-title":"Structure-based design of new potent and highly selective PARP-1 inhibitor for treating colorectal cancer","volume":"40","author":"Jiang","year":"2025","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115300","article-title":"An overview of compound properties, multiparameter optimization, and computational drug design methods for PARP-1 inhibitor drugs","volume":"252","author":"Hirlekar","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib53","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1186\/s12951-024-03020-3","article-title":"Radionuclide-labelled nanoparticles for cancer combination therapy: a review","volume":"22","author":"Sun","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.ejmech.2026.119185_bib54","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"PARP inhibitors in ovarian cancer: a review","volume":"18","author":"O'Malley","year":"2023","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.ejmech.2026.119185_bib55","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-21-2997","article-title":"ATR inhibitor AZD6738 (Ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib","volume":"82","author":"Wilson","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119185_bib56","doi-asserted-by":"crossref","first-page":"5626","DOI":"10.1158\/0008-5472.CAN-11-1227","article-title":"Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas","volume":"71","author":"Kummar","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119185_bib57","article-title":"Angiogenesis inhibitors for the treatment of epithelial ovarian cancer","volume":"4","author":"Gaitskell","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejmech.2026.119185_bib58","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus Carboplatin\/Paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.119185_bib59","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1158\/0008-5472.CAN-18-1273","article-title":"EGFR and c-MET cooperate to enhance resistance to PARP inhibitors in hepatocellular carcinoma","volume":"79","author":"Dong","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119185_bib60","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA damage response promotes antitumor immunity through STING-Mediated T-cell activation in small cell lung cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.119185_bib61","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918808509","article-title":"Inhibitors targeting CDK4\/6, PARP and PI3K in breast cancer: a review","volume":"10","author":"Nur Husna","year":"2018","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ejmech.2026.119185_bib62","article-title":"Beyond PARP-HDAC inhibition: mechanistic rationale and medicinal chemistry insights from single to shared-target strategies","volume":"180","author":"E","year":"2026","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib63","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ccell.2019.09.004","article-title":"Therapeutic targeting of CDK12\/CDK13 in triple-negative breast cancer","volume":"36","author":"Quereda","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2026.119185_bib64","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41416-020-0916-5","article-title":"First-in-human study of the PARP\/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor","volume":"123","author":"Plummer","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119185_bib65","doi-asserted-by":"crossref","first-page":"5460","DOI":"10.7150\/ijbs.113726","article-title":"JPI-547, a dual inhibitor of PARP\/Tankyrase, shows antitumor activity against pancreatic cancers with homologous recombination repair deficiency or wnt-addiction","volume":"21","author":"Oh","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.ejmech.2026.119185_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108847","article-title":"The LSD1\/HDAC dual-target inhibitor for cancer therapy: challenge and opportunity","volume":"164","author":"Shen","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib67","doi-asserted-by":"crossref","DOI":"10.4028\/b-XDTcg5","article-title":"Discovery of natural compound \u03b1\u2010Hederin via large\u2010scale screening as a targeted JAK\/STAT3 inhibitor for ovarian cancer therapy","volume":"12","author":"Wang","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejmech.2026.119185_bib68","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.drudis.2021.08.007","article-title":"Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: current situation and future directions","volume":"27","author":"Jin","year":"2022","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119185_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113963","article-title":"Dual target inhibitors based on EGFR: promising anticancer agents for the treatment of cancers (2017-)","volume":"227","author":"Hu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117773","article-title":"Design and synthesis of CDK9\/EZH2 dual-target inhibitors to achieve synergistic antitumor effects","volume":"294","author":"Tian","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2025.156298","article-title":"Chemical discovery of a novel MD2\/ADAM17 dual-target inhibitor as a potential therapeutic candidate for saturated fatty acid-induced myocardial inflammatory injury","volume":"169","author":"Zhang","year":"2025","journal-title":"Metabolism"},{"key":"10.1016\/j.ejmech.2026.119185_bib72","article-title":"Novel ATR\/PARP1 dual inhibitors demonstrate synergistic Antitumor efficacy in triple-negative breast cancer models","volume":"12","author":"Gao","year":"2025","journal-title":"Adv. Sci. (Weinh.)"},{"key":"10.1016\/j.ejmech.2026.119185_bib73","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1021\/acs.jmedchem.1c01757","article-title":"Design of a potent TLX agonist by rational fragment fusion","volume":"65","author":"Faudone","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib74","doi-asserted-by":"crossref","first-page":"12506","DOI":"10.1021\/acs.jmedchem.1c00163","article-title":"Pharmacophore-based design of Phenyl-[hydroxycyclohexyl] Cycloalkyl-Carboxamide mitofusin activators with improved neuronal activity","volume":"64","author":"Dang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib75","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-11-0348","article-title":"PI3K inhibition impairs BRCA1\/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition","volume":"2","author":"Ibrahim","year":"2012","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2026.119185_bib76","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1021\/acs.jmedchem.9b00622","article-title":"Discovery of novel dual Poly(ADP-ribose)polymerase and phosphoinositide 3-Kinase inhibitors as a promising strategy for cancer therapy","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113054","article-title":"Discovery of novel PARP\/PI3K dual inhibitors with high efficiency against BRCA-proficient triple negative breast cancer","volume":"213","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113357","article-title":"Discovery of novel and potent PARP\/PI3K dual inhibitors for the treatment of cancer","volume":"217","author":"Wu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib79","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/jcmm.17683","article-title":"Synergistic effect of PARP inhibitor and BRD4 inhibitor in multiple models of ovarian cancer","volume":"27","author":"Huang","year":"2023","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119185_bib80","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.apsb.2020.06.003","article-title":"Design, synthesis, and biological evaluation of quinazolin-4(3H)-one derivatives co-targeting poly(ADP-ribose) polymerase-1 and bromodomain containing protein 4 for breast cancer therapy","volume":"11","author":"Chang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119185_bib81","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1021\/acs.jmedchem.2c00135","article-title":"Discovery of 4-Hydroxyquinazoline derivatives as small molecular BET\/PARP1 inhibitors that induce defective homologous recombination and lead to synthetic lethality for triple-negative breast cancer therapy","volume":"65","author":"Zhang","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib82","doi-asserted-by":"crossref","first-page":"17413","DOI":"10.1021\/acs.jmedchem.1c01535","article-title":"Discovery of potent and novel dual PARP\/BRD4 inhibitors for efficient treatment of pancreatic cancer","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114116","article-title":"Design, synthesis and mechanism studies of novel dual PARP1\/BRD4 inhibitors against pancreatic cancer","volume":"230","author":"Huang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib84","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41388-024-03232-9","article-title":"EZH2 inhibition sensitizes MYC-high medulloblastoma cancers to PARP inhibition by regulating NUPR1-mediated DNA repair","volume":"44","author":"Yu","year":"2025","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.119185_bib85","doi-asserted-by":"crossref","first-page":"12630","DOI":"10.1021\/acs.jmedchem.1c00567","article-title":"Discovery of first-in-class dual PARP and EZH2 inhibitors for triple-negative breast cancer with wild-type BRCA","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116054","article-title":"Dual target PARP1\/EZH2 inhibitors inducing excessive autophagy and producing synthetic lethality for triple-negative breast cancer therapy","volume":"265","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118287","article-title":"Discovery of selective PARP1\/EZH2 inhibitor inducing PANoptosis in triple-negative breast cancer","volume":"302","author":"Fan","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib88","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.1016\/j.bmc.2017.05.058","article-title":"Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapy","volume":"25","author":"Yuan","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127036","article-title":"Design, synthesis and anticancer activities of novel dual poly(ADP-ribose) polymerase-1\/histone deacetylase-1 inhibitors","volume":"30","author":"Tian","year":"2020","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119185_bib90","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41419-023-06303-z","article-title":"Novel dual inhibitors of PARP and HDAC induce intratumoral STING-mediated antitumor immunity in triple-negative breast cancer","volume":"15","author":"Zhu","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2026.119185_bib91","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1021\/acs.jmedchem.4c00090","article-title":"Design, synthesis, and structure-activity relationship of novel pyridazinone-based PARP7\/HDACs dual inhibitors for elucidating the relationship between antitumor immunity and HDACs inhibition","volume":"67","author":"Duan","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib92","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1038\/onc.2014.105","article-title":"TACC3 deregulates the DNA damage response and confers sensitivity to radiation and PARP inhibition","volume":"34","author":"Ha","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.119185_bib93","doi-asserted-by":"crossref","first-page":"15702","DOI":"10.1021\/acs.jmedchem.1c00932","article-title":"Discovery of a dual tubulin and Poly(ADP-Ribose) Polymerase-1 inhibitor by structure-based pharmacophore modeling, virtual screening, molecular docking, and biological evaluation","volume":"64","author":"Zheng","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib94","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2276665","article-title":"Flavone-based dual PARP-Tubulin inhibitor manifesting efficacy against endometrial cancer","volume":"38","author":"Sharma","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.plipres.2021.101117","article-title":"PARPs in lipid metabolism and related diseases","volume":"84","author":"Szanto","year":"2021","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ejmech.2026.119185_bib96","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/cr.2012.52","article-title":"The Axin\/TNKS complex interacts with KIF3A and is required for insulin-stimulated GLUT4 translocation","volume":"22","author":"Guo","year":"2012","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2026.119185_bib97","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41416-026-03411-3","article-title":"JPI-547, a novel dual inhibitor of PARP1\/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1\/2-mutated cancer models","volume":"135","author":"Kang","year":"2026","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119185_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114417","article-title":"Rational design, synthesis and biological evaluation of dual PARP-1\/2 and TNKS1\/2 inhibitors for cancer therapy","volume":"237","author":"Xu","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102973","article-title":"PARP and PD-1\/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer","volume":"152","author":"Post","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2026.119185_bib100","doi-asserted-by":"crossref","first-page":"12584","DOI":"10.1021\/acsomega.9b01106","article-title":"Small-molecule Poly(ADP-ribose) polymerase and PD-L1 inhibitor conjugates as dual-action anticancer agents","volume":"4","author":"Ofori","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.119185_bib101","doi-asserted-by":"crossref","first-page":"10848","DOI":"10.1021\/acs.jmedchem.4c00296","article-title":"Novel bifunctional conjugates targeting PD-L1\/PARP7 as dual immunotherapy for potential cancer treatment","volume":"67","author":"Gao","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib102","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/cas.70042","article-title":"The combination of PARP and topoisomerase 1 inhibitors improves radiation therapy for ewing sarcoma","volume":"116","author":"Xie","year":"2025","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2026.119185_bib103","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.cclet.2019.06.019","article-title":"Design, synthesis and biological evaluation of novel phthalazinone acridine derivatives as dual PARP and Topo inhibitors for potential anticancer agents","volume":"31","author":"Dai","year":"2020","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119185_bib104","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.ejmech.2017.07.050","article-title":"Design, synthesis and biological evaluation of 4-amidobenzimidazole acridine derivatives as dual PARP and Topo inhibitors for cancer therapy","volume":"138","author":"Yuan","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115598","article-title":"Design, synthesis and development of a dual inhibitor of Topoisomerase 1 and poly (ADP-ribose) polymerase 1 for efficient killing of cancer cells","volume":"258","author":"Guha Majumdar","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116348","article-title":"Design, synthesis and biological evaluation of matrine contains benzimidazole derivatives as dual TOPOI and PARP inhibitors for cancer therapy","volume":"270","author":"Qiu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116739","article-title":"Synthesis of novel dual target inhibitors of PARP and EGFR and their antitumor activities in triple negative breast cancers","volume":"61","author":"Lin","year":"2022","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib108","doi-asserted-by":"crossref","first-page":"23644","DOI":"10.1039\/D2RA03549A","article-title":"Design and synthesis of new bis(1,2,4-triazolo[3,4-b][1,3,4]thiadiazines) and bis((quinoxalin-2-yl)phenoxy)alkanes as anti-breast cancer agents through dual PARP-1 and EGFR targets inhibition","volume":"12","author":"Thabet","year":"2022","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2026.119185_bib109","doi-asserted-by":"crossref","first-page":"5752","DOI":"10.1021\/acs.jmedchem.9b02008","article-title":"Design and synthesis of a trifunctional molecular system \"programmed\" to block epidermal growth factor receptor tyrosine kinase, induce high levels of DNA damage, and inhibit the DNA repair enzyme (Poly(ADP-ribose) polymerase) in prostate cancer cells","volume":"63","author":"Schmitt","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib110","doi-asserted-by":"crossref","first-page":"5445","DOI":"10.1158\/1078-0432.CCR-23-3785","article-title":"Synthetic lethal targeting of CDK12-Deficient prostate cancer with PARP inhibitors","volume":"30","author":"Chou","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119185_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106683","article-title":"Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCA","volume":"139","author":"Wang","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib112","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23052892","article-title":"A novel CDK4\/6 and PARP dual inhibitor ZC-22 effectively suppresses tumor growth and improves the response to cisplatin treatment in breast and ovarian cancer","volume":"23","author":"Tian","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119185_bib113","doi-asserted-by":"crossref","first-page":"13030","DOI":"10.1021\/acs.jmedchem.5c01058","article-title":"Design and synthesis of PARP\/CDK6 dual-target inhibitors modulating of Wnt\/beta-Catenin signaling pathway for the treatment of BRCA wild-type TNBC","volume":"68","author":"Zhang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115648","article-title":"Discovery of a novel dual-target inhibitor of CDK12 and PARP1 that induces synthetic lethality for treatment of triple-negative breast cancer","volume":"259","author":"Zhang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib115","doi-asserted-by":"crossref","first-page":"4916","DOI":"10.1021\/acs.jmedchem.4c00077","article-title":"Rational design of PARP1\/c-Met dual inhibitors for overcoming PARP1 inhibitor resistance induced by c-Met overexpression","volume":"67","author":"Sun","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2025.130117","article-title":"Discovery of dual PARP\/NAMPT inhibitors for the treatment of BRCA wild-type triple-negative breast cancer","volume":"120","author":"Mao","year":"2025","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119185_bib117","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1021\/acs.jmedchem.3c02096","article-title":"Discovery and proof of concept of potent dual Poltheta\/PARP inhibitors for efficient treatment of homologous recombination-deficient tumors","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119185_bib118","doi-asserted-by":"crossref","first-page":"22622","DOI":"10.1021\/jacs.2c09255","article-title":"Bridged proteolysis targeting chimera (PROTAC) enables degradation of undruggable targets","volume":"144","author":"Xiong","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2026.119185_bib119","article-title":"A PROTAC\u2010Based cuproptosis sensitizer in lung cancer therapy","volume":"37","author":"Wang","year":"2025","journal-title":"Adv. Mater."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:15:13Z","timestamp":1788048913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":119,"alternative-id":["S0223523426006306"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119185","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A comprehensive review of the mechanism and application prospect of PARP dual-target inhibitors in tumor treatment","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119185"}}